MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions

    Y-H. Chang, M. Periñan, A. Noyce (London, United Kingdom)

    Objective: To update on AccessPD's progress, emphasising the growth in patient recruitment, data integration, and the preliminary analysis aimed at advancing Parkinson's disease (PD) research.…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

    M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

    Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…
  • 2024 International Congress

    LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics

    D. Jennings, S. Huntwork-Rodriguez, J. Kluss, S. Ota, S. Dhuria, R. Maciuca, K. Fraser, B. Hersh, Z. Berger, C. Ho, P. Chin (South San Francisco, USA)

    Objective: To evaluate safety and biomarker effects of BIIB122/DNL151 in participants with pathogenic LRRK2 variants diagnosed with Parkinson’s disease (LRRK2-PD). Background: Increased LRRK2 kinase activity…
  • 2024 International Congress

    Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial

    M. Ansari, Y. Yang, S. Elliott, M. Naganawa, P. Honhar, M. Dias, S. Henry, J. Ropchan, R. Comley, N. Nabulsi, Y. Huang, R. Carson, S. Finnema, S. Nikayin, S. Tinaz, D. Matuskey, G. Sanacora, S. Holmes (New Haven, USA)

    Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…
  • 2024 International Congress

    TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.

    T. Pfeiffer, M. Ho, E. Duckworth, L. Tear, Z. Zahariev, L. Khederlarian, A. Plowright (Sevenoaks, United Kingdom)

    Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…
  • 2024 International Congress

    Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study

    S. Aslam, M. Olson, S. Felson, F. Ponce, H. Shill (Aurora, USA)

    Objective: To assess the feasibility of an aerobic exercise regimen in those with advanced PD and DBS. Background: Aerobic exercise is known to have beneficial…
  • 2024 International Congress

    Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability

    M. de Sciscio, R. Bryant, S. Haylock-Jacobs, A. Day, S. Costello, T. Kimber (Adelaide, Australia)

    Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…
  • 2024 International Congress

    One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

    V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

    Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…
  • 2024 International Congress

    A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion

    G. Lazzeri, C. Baiata, F. Del Sorbo, M. Corradi, M. Barichella, L. Caffi, C. Palmisano, P. Soliveri, G. Pezzoli, IU. Isaias (Milan, Italy)

    Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley